Select Page

Infinium Global Research has added a new report on Chronic Idiopathic Constipation Therapeutic Market. The report covers the analysis of global as well as regional markets of chronic idiopathic constipation therapeutic. Moreover, the report gives insights into the factors that affect the global as well as regional performance of the market in the short run and in the long run.

Ask for Sample Copy of Research Report with Table of Content @

Constipation can be defined as a state of unsatisfactory bowel movement, with characteristics of unusual stools and difficulty in passing stools, or both. Chronic idiopathic constipation (CIC) is an advancing condition without any known cause or identified underlying illness. Chronic idiopathic constipation is one of the most frequent gastrointestinal disorders globally with an evaluation of 35 million population living with chronic idiopathic constipation, affecting approximately 14% of the adults. CIC can be classified into three subtypes: dyssynergic defecation (DD), a problem with rectal evacuation; slow transit constipation; and normal transit constipation, which is the most common subtype. Patients with CIC usually have symptoms such as reduced frequency of defecation, hard or lumpy stools, straining at stool, a sensation of incomplete evacuation or blockage, and some may also complain about abdominal pain and bloating. In general, symptoms are chronic if they have been present for at least 3 months.

Changing lifestyle as well as modern food habits causing a decrease in fluid and fiber intake in the diet, changes in water balance and changes in contractility of the colon are the risk factors leading to chronic idiopathic constipation, thereby driving the chronic idiopathic constipation therapeutic market. Additionally, raising awareness about the treatment, increasing geriatric population and easy accessibility of over-the-counter drugs may also fuel the chronic idiopathic constipation therapeutic market.

However, less diagnosis due to lack of symptoms for the disease, alternative treatments and insufficient approved treatment for CIC may hinder the growth of the chronic idiopathic constipation therapeutic market. Increase in healthcare expenditure and extensive research in effective drugs manufacturing for treatment will increase the opportunity for chronic idiopathic constipation therapeutic market in the future.

North-America will Dominate the Market During the Forecast Period

Geographically the chronic idiopathic constipation therapeutic market is segmented in regions like North America, Europe, Asia Pacific, Middle East, and Africa. Due to the high prevalence of chronic idiopathic constipation, North-America will dominate the market during the forecast period. The Asia-pacific market is estimated to grow due to the rise in the acceptability of CIC treatments in countries like India and China. Whereas, the Europe market will develop in the future due to key players focus on new treatment and product launch for chronic idiopathic constipation.

Chronic Idiopathic Constipation Therapeutic Market: Segmentation

The report on the global chronic idiopathic constipation therapeutic market covers segments such as drug class, route of administration, and distribution channel. On the basis of drug class, the sub-markets include emollients, laxatives, bulk-forming agents, osmotic agents, and other drug class. On the basis of route of administration, the sub-markets include oral, and parental. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.

Chronic Idiopathic Constipation Therapeutic Market: Competitive Landscape

The report provides profiles of the companies in the market such as GlaxoSmithKline Plc., Bayer AG, Astellas Pharma, Inc., Sanofi S.A., Pfizer, Inc., Ironwood Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, and Other Companies.

Browse Detailed TOC, Description, and Companies Mentioned in Report @

Reasons to Buy this Report:

  • Comprehensive analysis of global as well as regional markets of the chronic idiopathic constipation therapeutic.
  • Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
  • Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
  • Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.